12 Most Profitable Stocks to Invest In

10. Gilead Sciences, Inc. (NASDAQ:GILD)

On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the first FDA-approved treatment for chronic HDV infection. Wendy Carter, Acting Director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said the approval fills a “critical gap in care” for patients who previously had no FDA-approved therapies.

On May 21, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) completed its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates. The acquisition adds Tubulis’ ADC assets and platform to Gilead, including TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC, and TUB-030, a 5T4-directed ADC. Under the agreement, Gilead acquired all outstanding equity of Tubulis for $3.15B upfront on a cash-free, debt-free basis, with up to $1.85B in contingent milestone payments. The Tubulis team will remain in Munich, Germany, where the Tubulis ADC Innovation Center will be established.

A day earlier, Maxim analyst Michael Okunewitch upgraded Gilead Sciences, Inc. (NASDAQ:GILD) to Buy from Hold with a $165 price target. Okunewitch said base business growth is expected to reach 5%-6%, above the prior expectation of 4%-5%. Maxim also cited the growth potential of Yeztugo in PREP, Trodelvy in first-line breast cancer, and continued dominance in HIV treatment, while noting that the stock’s pullback from all-time highs leaves its 15.1-times expected 2026 EPS multiple in line with biopharma peers.

Gilead Sciences, Inc. (NASDAQ:GILD) discovers, develops, and commercializes medicines for areas of unmet medical need in the United States, Europe, and internationally.